Baxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. The company also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSE:BAX
Previous Symbol
CUSIP07181310
Phone224-948-2000
Debt
Debt-to-Equity Ratio0.38
Current Ratio2.60
Quick Ratio1.96
Price-To-Earnings
Trailing P/E Ratio26.40
Forward P/E Ratio21.83
P/E Growth1.75
Sales & Book Value
Annual Sales$10.56 billion
Price / Sales3.30
Cash Flow$3.9493 per share
Price / Cash Flow16.58
Book Value$16.73 per share
Price / Book3.91
Profitability
EPS (Most Recent Fiscal Year)$2.48
Net Income$717 million
Net Margins10.90%
Return on Equity17.67%
Return on Assets9.49%
Miscellaneous
Employees47,000
Outstanding Shares532,140,000
Market Cap$34.60 billion
OptionableOptionable
Baxter International (NYSE:BAX) Frequently Asked Questions
What is Baxter International's stock symbol?
Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX."
How often does Baxter International pay dividends? What is the dividend yield for Baxter International?
Baxter International declared a quarterly dividend on Tuesday, November 13th. Shareholders of record on Monday, December 3rd will be given a dividend of $0.19 per share on Wednesday, January 2nd. This represents a $0.76 dividend on an annualized basis and a yield of 1.16%. The ex-dividend date is Friday, November 30th. View Baxter International's Dividend History.
How will Baxter International's stock buyback program work?
Baxter International declared that its Board of Directors has authorized a share buyback plan on Tuesday, November 13th 2018, which authorizes the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 6.1% of its shares through open market purchases. Shares buyback plans are often a sign that the company's management believes its shares are undervalued.
How were Baxter International's earnings last quarter?
Baxter International Inc (NYSE:BAX) announced its earnings results on Wednesday, October, 31st. The medical instruments supplier reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.06. The medical instruments supplier had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.79 billion. Baxter International had a net margin of 10.90% and a return on equity of 17.67%. The business's revenue for the quarter was up 2.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.64 earnings per share. View Baxter International's Earnings History.
When is Baxter International's next earnings date?
What guidance has Baxter International issued on next quarter's earnings?
Baxter International updated its fourth quarter earnings guidance on Wednesday, October, 31st. The company provided earnings per share guidance of $0.71-0.73 for the period, compared to the Thomson Reuters consensus estimate of $0.77. Baxter International also updated its FY 2018 guidance to $2.98-3.00 EPS.
What price target have analysts set for BAX?
16 Wall Street analysts have issued 1-year price objectives for Baxter International's shares. Their forecasts range from $66.00 to $85.00. On average, they expect Baxter International's share price to reach $74.6250 in the next year. This suggests a possible upside of 14.0% from the stock's current price. View Analyst Price Targets for Baxter International.
What is the consensus analysts' recommendation for Baxter International?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last year. There are currently 2 sell ratings, 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Baxter International.
Has Baxter International been receiving favorable news coverage?
News headlines about BAX stock have been trending very positive on Monday, according to InfoTrie. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Baxter International earned a news impact score of 3.9 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of Baxter International's key competitors?
Some companies that are related to Baxter International include 3M (MMM), Stryker (SYK), Becton Dickinson and (BDX), Boston Scientific (BSX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), ABIOMED (ABMD), Teleflex (TFX), DexCom (DXCM), Hill-Rom (HRC), Haemonetics (HAE), Insulet (PODD), ICU Medical (ICUI), Penumbra (PEN) and Globus Medical (GMED).
Who are Baxter International's key executives?
Baxter International's management team includes the folowing people:
- Mr. José E. Almeida, Chairman, Pres & CEO (Age 56)
- Mr. James K. Saccaro, Exec. VP & CFO (Age 45)
- Mr. Sean Martin, Sr. VP & Gen. Counsel (Age 55)
- Mr. Brik V. Eyre, Sr. VP & Pres of Americas (Age 54)
- Mr. Giuseppe Accogli, Sr. VP & Pres of Global Bus.es (Age 47)
Who are Baxter International's major shareholders?
Baxter International's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.41%), Vanguard Group Inc. (6.84%), FMR LLC (5.52%), Morgan Stanley (1.99%), AQR Capital Management LLC (1.26%) and Standard Life Aberdeen plc (1.08%). Company insiders that own Baxter International stock include Albert P L Stroucken, Brik V Eyre, Carole J Shapazian, Giuseppe Accogli, James R Gavin III, Jeanne K Mason, John D Forsyth, Peter S Hellman, Scott Pleau, Third Point Llc and Thomas T Stallkamp. View Institutional Ownership Trends for Baxter International.
Which institutional investors are selling Baxter International stock?
BAX stock was sold by a variety of institutional investors in the last quarter, including Veritas Asset Management LLP, BlackRock Inc., Wells Fargo & Company MN, Point72 Asset Management L.P., Mitsubishi UFJ Trust & Banking Corp, TIAA CREF Investment Management LLC, The Manufacturers Life Insurance Company and Acadian Asset Management LLC. Company insiders that have sold Baxter International company stock in the last year include Brik V Eyre, Carole J Shapazian, Giuseppe Accogli, James R Gavin III, Peter S Hellman, Scott Pleau and Third Point Llc. View Insider Buying and Selling for Baxter International.
Which institutional investors are buying Baxter International stock?
BAX stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Standard Life Aberdeen plc, Schroder Investment Management Group, FMR LLC, Prudential Financial Inc., Vanguard Group Inc., Thrivent Financial for Lutherans and Man Group plc. View Insider Buying and Selling for Baxter International.
How do I buy shares of Baxter International?
Shares of BAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Baxter International's stock price today?
One share of BAX stock can currently be purchased for approximately $65.48.
How big of a company is Baxter International?
Baxter International has a market capitalization of $34.60 billion and generates $10.56 billion in revenue each year. The medical instruments supplier earns $717 million in net income (profit) each year or $2.48 on an earnings per share basis. Baxter International employs 47,000 workers across the globe.
What is Baxter International's official website?
How can I contact Baxter International?
Baxter International's mailing address is One Baxter Parkway, DEERFIELD IL, 60015. The medical instruments supplier can be reached via phone at 224-948-2000 or via email at [email protected]
MarketBeat Community Rating for Baxter International (NYSE BAX)
MarketBeat's community ratings are surveys of what our community members think about Baxter International and other stocks. Vote "Outperform" if you believe BAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
